RASP-UK - Moving away from the ‘one size fits all’ approach to treatment in severe asthma

Partners

NHS Partners

  • Belfast Health & Social Care Trust
  • Oxford University Hospitals NHS Trust
  • Glenfield Hospital, University Hospitals of Leicester NHS Trust
  • Wythenshawe Hospital, University Hospitals of South Manchester NHS Trust
  • University Hospital Southampton NHS Foundation Trust
  • Royal Brompton & Harefield NHS Foundation Hospital
  • Kings College Hospital NHS Foundation Trust
  • Nottingham University Hospitals NHS Foundation Trust
  • Sheffield Teaching Hospitals NHS Foundation Trust
  • Gartnavel and Stobhill Hospitals, Greater Glasgow health Board
  • Heartlands Hospital, Heart of England NHS Foundation Trust
  • Freemans Hospital, Newcastle upon Tyne NHS Foundation Trust
  • University College London Hospitals NHS Trust

University Partners

  • Queen's University of Belfast
  • University of Leicester
  • Imperial College London
  • King's College London
  • University of Southampton
  • The University of Manchester
  • University of Oxford
  • University of Nottingham
  • University of Sheffield
  • University College London

Industry Partners

  • Aerocrine AB Global Clinical Development
  • Amgen Inc Amgen Corporation
  • AstraZeneca / MedImmune
  • Boehringer- Ingelheim Pharmaceuticals
  • GlaxoSmithKline
  • Hoffmann la Roche / Genentech Inc
  • Janssen Pharmaceutical Companies
  • Vitalograph Ireland

Other Partners

  • Niche Science & Technology
  • Asthma UK
  • AIRPROM (Airway Disease Predicting Outcomes through Patient Specific Computational Modelling)
  • UBIOPRED (Unbiased BIOmarkers in PREDiction of respiratory disease outcomes)
  • British Thoracic Society
  • ABPI (Association of the British Pharmaceutical Industry)
  • National Institute for Health Research (NIHR) Respiratory Biomedical Research Units and Clinical Research Facilities and the NIHR Inflammatory Respiratory Disease Translational Research Partnership
  • Royal College of Surgeons in Ireland
The RASP-UK Consortium will provide a world leading change in the care of patients with severe asthma.